A carregar...
Increasing frequency of combination medical therapy in the treatment of acromegaly with the GH receptor antagonist pegvisomant
Pegvisomant monotherapy is effective and safe in treatment of acromegaly. However, some clinicians combine pegvisomant with somatostatin analogues (SSA) or dopamine agonist (DA). In this analysis of ACROSTUDY, a long-term non-interventional study, the use of combination regimens was evaluated. Based...
Na minha lista:
| Publicado no: | Eur J Endocrinol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Bioscientifica Ltd
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5863474/ https://ncbi.nlm.nih.gov/pubmed/29371335 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1530/EJE-17-0996 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|